每经AI快讯，迪哲医药（SH 688192，收盘价：58.54元）12月15日晚间发布公告称，公司限售股份约 297.72万股将于2025年12月23日解禁并上市流通。 （记者 王晓波） 每经头条（nbdtoutiao）——"一针两千，童颜针年销3亿元"背后：多家关联方注册地"查无此人"，股民 追问"钱呢"！钱氏姐弟几乎"掏空"江苏吴中，公司即将退市 2024年1至12月份，迪哲医药的营业收入构成为：医药制造业占比100.0%。 截至发稿，迪哲医药市值为270亿元。 ...

证券代码：688192 证券简称：迪哲医药 公告编号：2025-61 迪哲（江苏）医药股份有限公司 一、本次上市流通的限售股类型 根据中国证券监督管理委员会于 2021 年 11 月 3 日出具的《关于同意迪哲（江 苏）医药股份有限公司首次公开发行股票注册的批复》（证监许可〔2021〕3494 号），迪哲（江苏）医药股份有限公司（以下简称"公司"）首次向社会公开发行人 民币普通股（A 股）40,000,100 股，并于 2021 年 12 月 10 日在上海证券交易所科 创板上市。发行完成后公司总股本为 400,000,100 股。 本次上市流通的限售股为公司首次公开发行前实施上市后行权的 2020 年员工 股份期权计划第二个行权期第一次行权限售股，其限售期为行权之日起 36 个月； 该部分行权新增股份已于 2022 年 12 月 23 日在中国证券登记结算有限责任公司上 海分公司完成登记，行权后公司总股本增至 407,160,297 股。本次上市流通的限售 股数量为 2,977,177 股，股东数量为 107 名。本次申请上市流通的限售股占截至本 公告发布之日公司总股本比例为 0.65%，将于 2025 年 ...

华泰联合证券有限责任公司关于 迪哲（江苏）医药股份有限公司 2020 年员工股份期权计划第二个行权期第一次行权限售股 上市流通的核查意见 一、本次上市流通的限售股类型 华泰联合证券有限责任公司（以下简称"保荐机构"）作为迪哲（江苏）医 药股份有限公司（以下简称"迪哲医药"或"公司"）2023 年度向特定对象发行 A 股股票的保荐机构，根据《证券发行上市保荐业务管理办法》《上海证券交易 所科创板股票上市规则》以及《上海证券交易所科创板上市公司自律监管指引第 1 号——规范运作》等相关规定履行持续督导职责，对迪哲医药 2020 年员工股 份期权计划第二个行权期第一次行权限售股上市流通事项进行了核查，核查的具 体情况如下： 1 在本次上市流通的限售股形成后，公司股本因 2020 年员工股份期权计划行 权登记合计新增 4,942,823 股，具体情况如下： | 序 | 股份变 | | | 股份变动事项 | 股份变动数 公告索引 | | --- | --- | --- | --- | --- | --- | | 号 | 动时间 | | | | 量（股） | | 1 | 2023 月 2 | 年 16 | 公司 2020 ...

Core Insights - The Chinese innovative drug industry has transitioned from "importing and imitating" to "innovative output" with a significant increase in the number of approved innovative drugs and a growing focus on international markets [1][2]. Group 1: Industry Trends - The number of approved innovative drugs in China has increased significantly, with 48 new drugs expected to be approved in 2024, more than five times the number in 2018, and a total of 63 approved as of October this year [1]. - The number of new drugs under research in China ranks second globally, indicating a robust pipeline for future innovations [1]. - The "outbound" model for Chinese innovative drugs is evolving from primarily external licensing to a more diversified approach that includes "borrowing, buying, and building" [2][7]. Group 2: Factors Driving Growth - The rapid growth in innovative drugs is attributed to long-term commitment to research and development, competitive pressures, and supportive policies that have accelerated the drug approval process [3][4]. - The approval process for new drugs has significantly shortened, with the time from clinical application to market approval reduced from several years to approximately 60 working days under current policies [4]. - The integration of innovative drugs into insurance coverage has also accelerated, with the time from approval to inclusion in the insurance catalog reduced from around five years to about one year [4]. Group 3: Market Opportunities - The expiration of patents for major products from leading multinational pharmaceutical companies by 2030 presents an opportunity for Chinese innovative drugs, particularly in oncology and immunotherapy [5]. - The overseas market for innovative drugs offers significantly higher returns, with some products priced up to ten times higher than in the domestic market [5][8]. - The establishment of new companies overseas for the development and commercialization of innovative drugs is becoming a common strategy among Chinese firms, allowing them to share in future capital gains [8]. Group 4: Technological Advancements - The use of artificial intelligence in drug discovery is enhancing the efficiency of research, allowing companies to screen vast databases of compounds in a fraction of the time previously required [5][6]. - The expectation for the innovation cycle in drug development is changing, with the traditional "three tens" law (one billion dollars, ten years, and a ten percent success rate) being challenged by new technologies and methodologies [6]. Group 5: Supportive Policies and Ecosystem - Local governments are increasingly focusing on building supportive ecosystems for the biopharmaceutical industry, with initiatives aimed at funding, talent cultivation, and technological advancement [9]. - The establishment of comprehensive support policies is crucial for fostering innovation and ensuring the long-term sustainability of the industry [11].

中国经济网北京12月11日讯 迪哲医药（688192.SH）近日发布2025年第三季度报告显示，2025年 第三季度，公司实现营业收入2.31亿元，同比增长71.46%；归属于上市公司股东的净利润-2.03亿元； 归属于上市公司股东的扣除非经常性损益的净利润-2.11亿元。 2025年前三季度，公司实现营业收入5.86亿元，同比增长73.23%；归属于上市公司股东的净利 润-5.80亿元；归属于上市公司股东的扣除非经常性损益的净利润-6.31亿元；经营活动产生的现金流量 净额为-4.24亿元。 | | | | | HATTA A SAMILA 年初至报告期 | | --- | --- | --- | --- | --- | | | | 本报告期比上 | | 末比上年同期 | | 项目 | 本报告期 | 年同期增减变 | 年初至报告期末 | | | | | 动幅度(%) | | 增减变动幅度 | | | | | | (%) | | 营业收入 | 231,299,714.08 | 71.46 | 586,301,134.90 | 73.23 | | 到海总额 | -203.910.752.21 | 不适用 | - ...

Core Insights - The article discusses significant developments in the pharmaceutical and healthcare industry, including leadership changes, regulatory approvals, and strategic collaborations aimed at enhancing treatment options for patients with complex conditions like brain metastases [14][4][12]. Policy Developments - The National Medical Products Administration (NMPA) is focusing on balancing safety and development, emphasizing the importance of legal administration and scientific regulation to protect the legitimate rights of enterprises and promote high-quality industry development [2]. Drug Approvals - Yuandong Biotech received a drug registration certificate for Brivaracetam tablets, marking it as the first generic drug approved under the new registration classification in China. The expected sales for the original drug are approximately 160,000 yuan in the first half of 2025 [4]. - Jiutian Pharmaceutical has received approval for clinical trials of JMHT06 for treating acute gouty arthritis [5]. Capital Market Activities - L'Oréal plans to increase its stake in Galderma by acquiring an additional 10% of shares, which will raise its total ownership to 20% by early 2026. This move includes the nomination of two non-independent directors from L'Oréal to Galderma's board [7]. Industry Collaborations - Baiyang Pharmaceutical is collaborating with multiple medical institutions to enhance treatment for brain metastases, including launching real-world studies with ZAP-X technology and establishing a precision radiotherapy center [12][9].

Core Viewpoint - Lingke Pharmaceutical (Zhejiang) Co., Ltd. has submitted its IPO application to the Hong Kong Stock Exchange, focusing on innovative small molecule inhibitors for autoimmune and inflammatory diseases, particularly in the JAK-STAT signaling pathway [1][2]. Company Overview - Lingke Pharmaceutical has completed multiple rounds of financing, raising over 1 billion RMB, with notable investments from institutions like Eli Lilly Asia Fund and Junlian Capital [1]. - The company has a strong focus on R&D, with its lead product LNK01001 currently in Phase III clinical trials for atopic dermatitis, rheumatoid arthritis, and ankylosing spondylitis [5][12]. Financial Performance - The company reported revenues of 20.573 million RMB in 2023, with projected revenues of 16.978 million RMB in 2024 and 54.780 million RMB in the first three quarters of 2025 [4]. - Lingke Pharmaceutical has incurred significant net losses, totaling 2.6 billion RMB in 2023, 3.12 billion RMB in 2024, and 1.45 billion RMB in the first three quarters of 2025, with cumulative losses reaching 7.17 billion RMB [2][4]. - As of September 30, 2025, the company had cash and cash equivalents of 147 million RMB, indicating a liquidity pressure with an estimated operational runway of about 15 months [3]. R&D Pipeline - The company is advancing several differentiated small molecule drugs targeting autoimmune and inflammatory diseases, with LNK01001 being the most advanced [5]. - LNK01004, a third-generation pan-JAK inhibitor, has shown promising results in Phase II trials and is expected to enter Phase III trials in mid-2027 [5]. - The IsoNova protein degradation platform has been established to enhance R&D efficiency, producing several preclinical candidates [5]. Market Landscape - The JAK inhibitor market is experiencing significant growth, with global market size projected to expand from $5.5 billion in 2019 to $25.6 billion by 2028 [7][8]. - The Chinese market for JAK inhibitors is also expected to grow from 400 million RMB in 2019 to 17.1 billion RMB by 2028, indicating strong clinical demand [7][8]. - Lingke Pharmaceutical's LNK01001 faces competition from established products in the market, which may impact its commercial success [12].

Group 1 - Wanma Technology has been pre-awarded a total of 59.9434 million yuan for multiple State Grid projects, which accounts for 14.49% of its latest audited main business revenue [1] - Tianen Kang's subsidiary received a drug registration certificate for Methimazole tablets, a medication used for hyperthyroidism [2] - Taijing Technology invested 10 million yuan to establish a special fund focused on high-speed network communication chips [3] Group 2 - Youyou Foods plans to use 10 million yuan of its own funds to purchase principal-protected financial products with an expected annual yield of 0.5%-5.0% [4] - Yangfan New Materials announced the release of detention measures against its controlling shareholder, allowing him to resume his duties [5] - Xianju Pharmaceutical received approval for a supplementary application for Nicardipine injection, a calcium channel blocker used for acute hypertension [6] Group 3 - Jingu Co. plans to repurchase shares worth 30-60 million yuan for employee stock ownership plans or equity incentives [7] - Double Tower Foods' Thai subsidiary has completed the construction of its production line and is in the initial production phase [8] - Tongyi Zhong intends to invest approximately 198 million yuan in a project for the industrialization of ultra-high molecular weight polyethylene fibers [9][10] Group 4 - Zhangyue Technology received a dividend of 4.99 million yuan from its stake in Dianzhong Technology, which represents 10.12% of its audited net profit for 2024 [11] - Sihua Electronics announced the resignation of its general manager due to job transfer, with the current manager continuing until a new one is appointed [12] - Jiutian Pharmaceutical's new drug JMHT06 has received approval for clinical trials for acute gouty arthritis [13] Group 5 - Anlian Ruishi has established a joint venture for embodied intelligent robots with a registered capital of 20 million yuan [14] - Kelin Electric's application for a private placement has been accepted by the Shanghai Stock Exchange [15] - Guoyao Modern's subsidiary has received approval for the listing of Agomelatine raw materials, used in antidepressant synthesis [16] Group 6 - Xintiandi's application for the listing of Ferrous Fumarate raw materials has been approved, which is used for treating iron deficiency anemia [17] - ST Weihai, as the leading party, won a bid for a smart agriculture project worth 652 million yuan, accounting for 26.27% of its 2024 audited revenue [18] - Tian Youwei plans to purchase 100% of Krämer Automotive Systems for 1 million euros [19] Group 7 - Guangdong Yuedian A's subsidiary has successfully put into operation the third unit of its Dapu Power Plant project [20] - China Life's total premium exceeded 700 billion yuan as of November 30, 2025 [21] - Shoukai Co. achieved a total signed amount of 15.988 billion yuan in the first 11 months of 2025 [22] Group 8 - Kehua Bio's subsidiary has obtained a medical device registration certificate for an automatic chemiluminescence immunoassay analyzer [23] - Chengyi Pharmaceutical received a drug registration certificate for Torasemide tablets, which have passed the consistency evaluation [24] - Chongqing Construction won a bid for a municipal engineering project worth approximately 1.714 billion yuan [25] Group 9 - Hanjian Heshan signed a procurement contract for pipes worth 388 million yuan [26] - Jiuzhou Pharmaceutical plans to use up to 1 billion yuan of idle raised funds for cash management [27] - Xinwufeng reported an 80.97% year-on-year increase in pig sales in November 2025 [28] Group 10 - Luoniushan reported a 13.57% year-on-year increase in pig sales revenue in November 2025 [29] - Fushilai received a drug registration certificate for Alpha-Lipoic Acid tablets, used for diabetic neuropathy [30] - Dizhe Pharmaceutical presented research data on two innovative drugs at the 67th American Society of Hematology conference [31] - David Medical's subsidiary received two medical device registration certificates for single-use gastric tubes and electronic ureteral endoscope catheters [32]

迪哲（江苏）医药股份有限公司 自愿披露关于高瑞哲®和 Birelentinib 最新研究数据 在第 67 届美国临床血液学会（ASH）发布的公告 本公司董事会及全体董事保证公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 证券代码：688192 证券简称：迪哲医药 公告编号：2025-60 迪哲（江苏）医药股份有限公司（以下简称"公司"）在第 67 届美国临床 血液学会（American Society of Hematology，ASH）大会上，公布了公司自主研 发的两款全球首创新药的最新研究成果：高选择性 JAK1 抑制剂高瑞哲®（通用 名：戈利昔替尼胶囊）在 T 细胞淋巴瘤领域取得多项新进展，以及非共价 LYN/BTK 双靶点抑制剂 birelentinib（DZD8586）在 B 细胞淋巴瘤治疗领域的最 新临床数据。 一、高瑞哲®在 T 细胞淋巴瘤领域的最新进展 1. 外周 T 细胞淋巴瘤（PTCL）一线治疗 在新诊断外周 T 细胞淋巴瘤患者中，高瑞哲®联合 CHOP 化疗治疗的两种给 药方案探索，均展现出令人鼓舞的抗肿瘤疗效和可控的安全性，有 ...

Core Viewpoint - The company, DIZH Medical (688192.SH), announced significant advancements in two globally innovative drugs at the 67th American Society of Hematology (ASH) conference, focusing on treatments for T-cell and B-cell lymphomas [1] Group 1: Drug Developments - The high-selectivity JAK1 inhibitor, Golixtin (generic name: Golixtin capsules), has made multiple new progressions in the field of T-cell lymphoma [1] - The non-covalent LYN/BTK dual-target inhibitor, birelentinib (DZD8586), has presented the latest clinical data for the treatment of B-cell lymphoma [1]